Shkreli is facing eight counts of securities and wire fraud in connection to an alleged Ponzi-like scheme involving one of his old pharmaceutical companies, Retrophin. Jury selection begins Monday morning.
Shkreli is being represented by a high-powered legal team headed by Benjamin Brafman, whose past clients have included Dominique Strauss-Kahn, the International Monetary Fund chief who was accused of sexually assaulting a hotel maid.
Retrophin is paying Shkreli's criminal defense fees, which are believed to be as high as $4.8 million.
At a hearing last Monday, prosecutors cited public boasts about his wealth in refusing to reduce Shkreli's bail from $5 million to $2 million United States, as he had requested, citing the need to pay taxes and legal bills. He also offered $40,000 for a math proof and $100,000 for tips on the killing of DNC staffer Seth Rich.
Another juror pretended to wring Shkreli's neck as he sat several feet away in the courtroom, saying she viewed him as "a person who puts profit over everything else", the Daily Beast reported.
"Martin Shkreli testifies before a House committee hearing on drug market oversight" in Washington in February 2016. His ownership stake in Turing Pharmaceutics, which hiked the price of the drug Daraprim, is worth $30 million to $50 million, but his lawyer says the he can'tsell it without shareholder approval.
Brafman also outlined the millions of dollars Shkreli owes to the IRS, a civil law firm and an accounting firm, as well as other outstanding debts.
Prosecutors are expected to call as many as 57 witnesses, and lawyers on both sides said the trial could last five to six weeks. One potential juror blamed Shkreli for the skyrocketing price of EpiPens, which are made by Mylan, a pharmaceutical company that has no connection with Shkreli.
Shkreli gained infamy in 2015 when, as the CEO of Turing Pharmaceuticals, he raised the cost of an anti-parasite drug often prescribed to HIV/AIDS patients by 5,000 percent, from $13.50 a pill to $750. Shkreli's trial is unrelated to the congressional inquiry. The persona includes him regularly live-streaming parts of his life and vilified on social media as a "pharma bro".